摘要
目的评价奥沙利铂联合卡培他滨(XELOX)方案与奥沙利铂联合5-氟尿嘧啶、亚叶酸钙(FOLFOX4)方案治疗进展期胃癌的疗效及安全性。方法将78例进展期胃癌患者随机分为XELOX组和FOLFOX4组,各39例,分别采取XELOX方案和FOLFOX4方案进行规范治疗,比较2组临床疗效及不良反应。结果 XELOX组总有效率(ORR)为56.41%,疾病控制率(DCR)为87.18%,中位肿瘤进展时间(TTP)6.3个月,中位生存时间(MST)13.9个月;FOLFOX4组ORR为51.28%,DCR为84.62%,中位TTP 6.1个月,MST 13.5个月。2组ORR、DCR、中位TTP及MST比较,差异均无统计学意义(P>0.05)。XELOX组白细胞减少,恶心、呕吐,腹泻及口腔黏膜炎发生率显著低于FOLFOX4组(P<0.05或P<0.01),仅手足综合征发生率显著高于FOLFOX4组(P<0.05)。结论 XELOX方案和FOLFOX4方案对进展期胃癌均有近55%的有效率,远期疗效也相近,但XELOX方案安全性更高。
Objective To evaluate the efficacy and safety of oxaliplatin plus capecitabine（ XELOX） and oxaliplatin plus 5- fluorouracil and calcium folinate（ FOLFOX4） regimens in the treatment of patients with advanced gastric carcinoma. Methods Seventy-eight patients with advanced gastric carcinoma were randomly divided into XELOX group（ n = 39） treated with XELOX regimen and FOLFOX4 group（ n = 39） treated with FOLFOX4 regimen. The clinical efficacy and adverse reactions were compared in two groups. Results The overall response rate（ ORR）,disease control rate（ DCR）,median time to tumor progression（ TTP） and median survival time（ MST） in XELOX group were 56. 41%,87. 18%,6. 3 months and 13. 9 months. The ORR,DCR,median TTP and MST in FOLFOX4 group were 51. 28%,84. 62%,6. 1 months and 13. 5 months. There were no significant differences in the ORR,DCR,median TTP and MST between two groups（ P〉 0. 05）. Compared with FOLFOX4 group,the incidence rates of leucopenia,nausea,vomiting,diarrhea and oral mucositis in XELOX group were lower significantly（ P〈 0. 05 or P〈 0. 01）,but incidence rate of hand-foot syndrome was significantly higher（ P〈 0. 05）. Conclusion The response rates of XELOX and FOLFOX4 regimens are close to 55% in the treatment of advanced gastric carcinoma,and their long- term efficacy is similar. However,XELOX regimen has higher safety.
出处
《实用临床医药杂志》
CAS
2016年第9期64-66,共3页
Journal of Clinical Medicine in Practice
关键词
进展期胃癌
卡培他滨
奥沙利铂
氟尿嘧啶
亚叶酸钙
advanced gastric carcinoma
capecitabine
oxaliplatin
fluorouracil
calcium folinate
